Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Knopp | $500,000 | $0 | $393,751 | $131,251 | $525,000 | $0 | $3,500 | $1,553,502 |
| President and Chief Executive Officer | ||||||||
| Mark Levine | 21,635 | 0 | 656,257 | 656,254 | 0 | 0 | 0 | 1,334,146 |
| Chief Legal and Administrative Officer and Secretary | ||||||||
| Joseph Griffith | 378,352 | 200,000 | 258,228 | 86,075 | 214,904 | 0 | 3,500 | 1,141,059 |
| Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kevin Knopp | $1,553,502 | $1,993,294 | — | −439,792 |
| Mark Levine | 1,334,146 | — | — | — |
| Joseph Griffith | 1,141,059 | 1,238,139 | — | −97,080 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kevin Knopp | RSU | 198,864 | — | $1,044,036 |
| Joseph Griffith | RSU | 130,418 | — | 684,695 |
| Mark Levine | RSU | 98,242 | — | 515,771 |
| Kevin Knopp | PSU | 53,794 | — | 282,418 |
| Kevin Knopp | RSU | 51,021 | — | 267,860 |
| Joseph Griffith | RSU | 33,781 | — | 177,350 |
| Kevin Knopp | RSU | 26,897 | — | 141,209 |
| Joseph Griffith | RSU | 20,612 | — | 108,213 |
| Kevin Knopp | RSU | 11,255 | — | 59,089 |
| Joseph Griffith | RSU | 5,102 | — | 26,787 |
| Kevin Knopp | Option | 3,115 | 16.66 | — |
| Kevin Knopp | Option | 50,341 | 7.35 | — |
| Kevin Knopp | Option | 90,518 | 1.98 | — |
| Joseph Griffith | Option | 1,412 | 16.66 | — |
| Joseph Griffith | Option | 18,242 | 8.83 | — |
| Joseph Griffith | Option | 33,331 | 7.35 | — |
| Joseph Griffith | Option | 59,362 | 1.98 | — |
| Mark Levine | Option | 130,468 | 6.68 | — |
The compensation committee targets a general competitive position based on independent third-party benchmark analytics to inform the mix of base salary, bonus, and long-term incentives. The program is designed to motivate employees to achieve short- and long-term results in the best interests of stockholders, align executive interests with stockholders through equity grants, and promote retention.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Meridian Compensation Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 21,187,486 | 2,748,574 | 388,820 | 87.1% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | 87.1%a |
a. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total and will have the same effect as "Against" votes.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| E. Kevin HrusovskyIndependent · Nominating and Corporate Governance | $87,500 | $101,257 | $33,753 | — | $0 | $222,510 |
| Brandi C. VannIndependent | 16,667 | 100,004 | 99,959 | — | 0 | 216,630 |
| Brandi C. Vann, Ph.DIndependent · Audit | 16,667 | 100,004 | 99,959 | — | 0 | 216,630 |
| Keith L. CrandellIndependent · Compensation | 67,500 | 101,257 | 33,753 | — | 0 | 202,510 |
| Fenel M. EloiIndependent · Audit (Chair) · Compensation | 65,417 | 101,257 | 33,753 | — | 0 | 200,427 |
| Mark SpotoIndependent · Nominating and Corporate Governance (Chair) · Audit | 65,000 | 101,257 | 33,753 | — | 0 | 200,010 |
| Tony J. HuntIndependent · Compensation (Chair) | 48,333 | 101,257 | 33,753 | — | 0 | 183,343 |
| Michele M. LeonhartIndependent · Nominating and Corporate Governance | 40,000 | 101,257 | 33,753 | — | 0 | 175,010 |
| Jeffrey P. GeorgeIndependent · Departed during FY | 35,000 | 101,257 | 33,753 | — | 0 | 170,010 |
| Marcia EisenbergIndependent | 22,917 | 0 | 0 | — | 0 | 22,917 |
| Marcia Eisenberg, Ph.DIndependent · Departed during FY | 22,917 | 0 | 0 | — | 0 | 22,917 |
| Christopher Brown, Ph.DNot independent · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Kevin J. Knopp, Ph.DEmployee director | — | — | — | — | — | 0 |
| Christopher BrownIndependent | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $135,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 10,000 / 7,500 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $487,918 |
| Equity awards (grant-date value) | $908,807 |
| All other compensation | $0 |
| Total cost of the board | $1,396,725 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies 908 Devices names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including 908 Devices.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Blackline Safety Corp. | 2025 | Owen Ryan | $524,231 | $5,694,941 | $4,908,126 | $473,378 | $11,614,676 |
| 2 | Standard BioTools Inc. | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 3 | Castle Biosciences, Inc. | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 4 | Butterfly Network, Inc. | 2025 | Joseph DeVivo | 900,300 | 4,291,604 | 0 | 1,183,000 | 6,382,814 |
| 5 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 6 | Surmodics, Inc. | 2024 | Gary Maharaj | 647,481 | 940,000 | 1,410,000 | 654,215 | 3,665,496 |
| 7 | MaxCyte, Inc. | 2025 | Maher Masoud | 590,000 | 1,143,275 | 625,300 | 313,290 | 2,687,657 |
| 8 | 908 Devices | 2025 | Kevin Knopp | 500,000 | 393,751 | 131,251 | 525,000 | 1,553,502 |
| 9 | Zynex, Inc. | 2024 | Thomas Sandgaard | 700,000 | 112,458 | 0 | 170,625 | 991,810 |
| 10 | Harvard Bioscience, Inc. | 2025 | John Duke | 203,077 | 598,900 | 0 | 0 | 905,208 |
| 11 | Stereotaxis, Inc. | 2025 | David Fischel | 60,000 | 0 | 0 | 0 | 64,390 |
| — | Bionano Genomics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Personalis, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Rapid Micro Biosystems, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Byrna Technologies Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Akoya Biosciences, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Genasys Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Apyx Medical Corporation | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| 908 Devices | not disclosed | RSU 75 · Option 25 | not disclosed | Meridian Compensation Partners, LLC |
| Akoya Biosciences, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Apyx Medical Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| Bionano Genomics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Blackline Safety Corp. | 90.1% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia |
| Butterfly Network, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Byrna Technologies Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Castle Biosciences, Inc. | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| Genasys Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Harvard Bioscience, Inc. | 0% | RSU 50 · MSU 50 | Yes — Relative Total Shareholder Return (TSR) | Frederic W. Cook & Co., Inc. |
| MaxCyte, Inc. | 88.5% | not disclosed | No | Pearl Meyer |
| Personalis, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Rapid Micro Biosystems, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Standard BioTools Inc. | 160% | not disclosed | not disclosed | Pearl Meyer |
| Stereotaxis, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Surmodics, Inc. | 126.3% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| Zynex, Inc. | 24.4% | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kevin Knopp | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Executive Compensation”. As printed: 1,553,502. Filing ↗machine: r1 · c47 · span 360944–360953 |
| 2 | Section 01, Mark Levine | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Executive Compensation”. As printed: 1,334,146. Filing ↗machine: r5 · c47 · span 380048–380057 |
| 3 | Section 01, Joseph Griffith | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Executive Compensation”. As printed: 1,141,059. Filing ↗machine: r3 · c47 · span 370429–370438 |
| 4 | Section 08, E. Kevin Hrusovsky | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 222,510. Filing ↗machine: span 676254–676261 |
| 5 | Section 08, Brandi C. Vann | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 216,630. Filing ↗ |
| 6 | Section 08, Brandi C. Vann, Ph.D | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 216,630. Filing ↗machine: span 688723–688730 |
| 7 | Section 08, Keith L. Crandell | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 202,510. Filing ↗machine: span 663680–663687 |
| 8 | Section 08, Fenel M. Eloi | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 200,427. Filing ↗machine: span 669967–669974 |
| 9 | Section 08, Mark Spoto | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 200,010. Filing ↗machine: span 685540–685547 |
| 10 | Section 08, Tony J. Hunt | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 183,343. Filing ↗machine: span 679356–679363 |
| 11 | Section 08, Michele M. Leonhart | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 175,010. Filing ↗machine: span 682440–682447 |
| 12 | Section 08, Jeffrey P. George | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 170,010. Filing ↗machine: span 673171–673178 |
| 13 | Section 08, Marcia Eisenberg | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 22,917. Filing ↗ |
| 14 | Section 08, Marcia Eisenberg, Ph.D | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 22,917. Filing ↗machine: span 664885–664891 |
| 15 | Section 08, Christopher Brown, Ph.D | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 08, Kevin J. Knopp, Ph.D | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 08, Christopher Brown | DEF 14A | 2026-04-29 | 0001104659-26-050795 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 06, 2026 vote | Form 8-K | 2026-06-12 | 0001104659-26-073487 | Item 5.07 · say-on-pay result. As reported: 87.1% (votes for as printed: 21,187,486). Filing ↗ |
| 19 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 20 | Section 09b board cost (computed) | Computed | — | computed | Cash 487,918 + equity 908,807 + all other 0 = 1,396,725, summed across the director compensation table rows.machine: formula: Σ = 1,396,725 |
| 21 | Blackline Safety Corp., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001628280-26-020925 | CEO total compensation as printed in Blackline Safety Corp.'s own proxy. As printed: 11,614,676. Filing ↗machine: r2 · c54 · span 948504–948514 |
| 22 | Standard BioTools Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017100 | CEO total compensation as printed in Standard BioTools Inc.'s own proxy. As printed: 8,823,502. Filing ↗machine: r2 · c22 · span 553256–553266 |
| 23 | Castle Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001628280-26-024166 | CEO total compensation as printed in Castle Biosciences, Inc.'s own proxy. As printed: 6,786,771. Filing ↗machine: r3 · c24 · span 933087–933096 |
| 24 | Butterfly Network, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017118 | CEO total compensation as printed in Butterfly Network, Inc.'s own proxy. As printed: 6,382,814. Filing ↗machine: r2 · c22 · span 387435–387444 |
| 25 | Quanterix Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048166 | CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085 |
| 26 | Surmodics, Inc., Section 10b CEO total | DEF 14A | 2024-12-19 | 0000950170-24-138240 | CEO total compensation as printed in Surmodics, Inc.'s own proxy. As printed: 3,665,496. Filing ↗machine: t109 · r3 · c25 · span 1568790–1568799 |
| 27 | MaxCyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017844 | CEO total compensation as printed in MaxCyte, Inc.'s own proxy. As printed: 2,687,657. Filing ↗machine: r2 · c21 · span 315402–315411 |
| 28 | 908 Devices (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050795 | CEO total compensation as printed in 908 Devices's own proxy. As printed: 1,553,502. Filing ↗machine: r1 · c47 · span 360944–360953 |
| 29 | Zynex, Inc., Section 10b CEO total | DEF 14A | 2025-03-28 | 0001558370-25-004019 | CEO total compensation as printed in Zynex, Inc.'s own proxy. As printed: 991,810. Filing ↗machine: t66 · r5 · c14 · span 277902–277909 |
| 30 | Harvard Bioscience, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001171843-26-002617 | CEO total compensation as printed in Harvard Bioscience, Inc.'s own proxy. As printed: 905,208. Filing ↗machine: r2 · c25 · span 341394–341401 |
| 31 | Stereotaxis, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001493152-26-015027 | CEO total compensation as printed in Stereotaxis, Inc.'s own proxy. As printed: 64,390. Filing ↗ |
| 32 | Section 10a, Blackline Safety Corp. reciprocity | DEF 14A | — | 0001628280-26-020925 | Blackline Safety Corp.'s most recent proxy was read; its disclosed peer group does not include 908 Devices. Filing ↗ |
| 33 | Section 10a, Harvard Bioscience, Inc. reciprocity | DEF 14A | — | 0001171843-25-002341 | Harvard Bioscience, Inc.'s most recent proxy was read; its disclosed peer group does not include 908 Devices. Filing ↗ |
| 34 | Section 10a, Castle Biosciences, Inc. reciprocity | DEF 14A | — | 0001628280-26-024166 | Castle Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include 908 Devices. Filing ↗ |
| 35 | Section 10a, Quanterix Corporation reciprocity | DEF 14A | — | 0001104659-26-048166 | Quanterix Corporation's most recent proxy was read; its disclosed peer group does not include 908 Devices. Filing ↗ |
| 36 | Section 10a, Zynex, Inc. reciprocity | DEF 14A | — | 0001558370-25-004019 | Zynex, Inc.'s most recent proxy was read; its disclosed peer group does not include 908 Devices. Filing ↗ |
| 37 | Section 10a, Standard BioTools Inc. reciprocity | DEF 14A | — | 0001140361-26-017100 | Standard BioTools Inc.'s most recent proxy was read; its disclosed peer group does not include 908 Devices. Filing ↗ |
| 38 | Section 10a, Surmodics, Inc. reciprocity | DEF 14A | — | 0000950170-24-138240 | Surmodics, Inc.'s most recent proxy was read; its disclosed peer group does not include 908 Devices. Filing ↗ |